Europe Market Report for Bone Morphogenic Protein Growth Factor Therapy 2017 - MedCore is a new market research publication announced by Reportstack.
General Report Contents• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
This market went through a decline a result of Olympus exiting the market with its OP-1® BMP-7 product. However, the market has stabilized and is expected to a growth over the forecast period. Despite the recently acquired approval for Infuse® to be used as an adjunct in all spinal interbody fusion procedures, the level of absorption will remain limited due to the two products’ substantially different indications. As such, unless InductOS® can build upon its indications, the market is expected to grow at a slower rate over the forecast period.
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
This market went through a decline a result of Olympus exiting the market with its OP-1® BMP-7 product. However, the market has stabilized and is expected to a growth over the forecast period. Despite the recently acquired approval for Infuse® to be used as an adjunct in all spinal interbody fusion procedures, the level of absorption will remain limited due to the two products’ substantially different indications. As such, unless InductOS® can build upon its indications, the market is expected to grow at a slower rate over the forecast period.
Complete report available @ Europe Market Report for Bone Morphogenic Protein Growth Factor Therapy 2017 - MedCore
In addition to the market value, the contracting ASP was also a result of the discontinuation of OP-1®, which was sold at a premium compared to InductOS®. Prices will remain stable throughout the remainder of the forecast period as Medtronic has no immediate plans to change its pricing scheme for the product. Furthermore, with the newly monopolized market, it is expected that demand for the product will remain fairly inelastic to any changes in price.
The countries with the largest BMP market in 2016 were France and Germany, with France being the leader. The negotiated reimbursement in France has allowed it to secure a large share of the overall European market. Germany, the largest country by population, was the second largest consumer; penetrating the German market remains difficult as Medtronic is tasked with proactively negotiating the reimbursement rates with various health insurers. Meanwhile, Austria and Portugal remained the smallest of the markets.
The countries with the largest BMP market in 2016 were France and Germany, with France being the leader. The negotiated reimbursement in France has allowed it to secure a large share of the overall European market. Germany, the largest country by population, was the second largest consumer; penetrating the German market remains difficult as Medtronic is tasked with proactively negotiating the reimbursement rates with various health insurers. Meanwhile, Austria and Portugal remained the smallest of the markets.
Scope
2013-2023
2013-2023
Companies Mentioned
Fidia Medtronic TRB Chemedica Meda Pharma Sanofi Genzyme Depuy Synthes Bioventus Laboratoire Genevrier Recordati Stryker RTI Biologics Croma-Pharma Zimmer Biomet Others include: Anika Therapeutics, Bioiberica, Documedica, Ferring, Geistlich, Integra Biologics, Kuros, LCA Pharma, Orotech, Plasmaconcept AG, Stella PharmaceuticalsAlphatec Spine, etc
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
No comments:
Post a Comment